Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 2Phase 2/3 1Phase 1 1

Status

Recruiting 5Unknown 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 9INDUSTRY 1

Study Type

Interventional 8Observational 2

Sponsor

Conditions

Breast Neoplasms 13110Neoplasms 10462Carcinoma, Non-Small-Cell Lung 6857Prostatic Neoplasms 6258Colorectal Neoplasms 5925Lung Neoplasms 5091Multiple Myeloma 3568Pancreatic Neoplasms 3552Leukemia, Myeloid, Acute 3503Neoplasm Metastasis 3499Carcinoma, Hepatocellular 3264Ovarian Neoplasms 3160Melanoma 3134Stomach Neoplasms 3051Lymphoma 2981Head and Neck Neoplasms 2595Recurrence 2548Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Leukemia 2360Colonic Neoplasms 2326Brain Neoplasms 2306Lymphoma, Non-Hodgkin 2265Rectal Neoplasms 2186Uterine Cervical Neoplasms 2182Glioblastoma 2010Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1910Squamous Cell Carcinoma of Head and Neck 1875Lymphoma, Follicular 1847Esophageal Neoplasms 1797

Interventions

Sorafenib 2nimotuzumab 1lenvatinib 1atezolizumab 1Tirapazamine 1Stents 1Radiotherapy 1Radiosurgery 1Radiofrequency Ablation 1Immune Checkpoint Inhibitors 1Hematologic Tests 1Ethiodized Oil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

10 trials
RecentStart dateEnrollment
HCC × Clear all
NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting
40 enrolled

HCC

NCT06844357 2025-04-06

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Zhejiang Raygene Pharmaceuticals Co., Ltd

Phase 2/3 Recruiting
300 enrolled

HCC

NCT05873244 2025-03-21

CXD101 in Immunotherapy-related Liver Cancer

Chinese University of Hong Kong

Phase 2 Recruiting
44 enrolled

HCC

NCT06766773 2025-01-10

CWSRIH-HCC

The First People's Hospital of Neijiang

Phase NA Active not recruiting
80 enrolled

HCC

NCT06463444 2024-06-17

Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

Tongji Hospital

Phase 1 Recruiting
30 enrolled

HCC

NCT06413017 2024-05-14

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
30 enrolled

HCC

NCT05825196 2023-04-24

Study of Serum Tumor Markers of HBV Associated HCC

Qianfoshan Hospital

Unknown
164 enrolled

HCC

NCT04123340 2023-01-06

IAMCOMPLETE

Leiden University Medical Center

Phase 2 Completed
20 enrolled

HCC

NCT03108248 2017-04-11

ISP-TACE Versus TACE for HCC With PVTT

Zhongda Hospital

Completed
126 enrolled

HCC

NCT01470495 2017-03-28

REPEAT

Southwest Hospital, China

Phase NA Unknown
430 enrolled

HCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡